A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma | MicrobiomeTrials← Back to trialsNCT04139304
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
RecruitingEARLY_PHASE1INTERVENTIONAL
Trial Details
Start: 2021-05-24Est. Completion: 2029-07
Enrollment target: 15 participants Locations- University of Miami Miller School of Medicine, Miami, Florida, United States
- University of Illinois at Chicago, Chicago, Illinois, United States
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
- The Ohio State University, Columbus, Ohio, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Other microbiome trials you might be interested in
AIDS-Related Diffuse Large B-cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma With MYC and BCL2 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedLugano Classification Stage II Adult Non-Hodgkin Lymphoma AJCC v8Lugano Classification Stage III Adult Non-Hodgkin Lymphoma AJCC v8Lugano Classification Stage IV Adult Non-Hodgkin Lymphoma AJCC v8Plasmablastic LymphomaPrimary Effusion Lymphoma
This phase I trial studies the safety and side effects of glofitamab plus a chemoimmunotherapy regimen called R-CHOP (ri…
Multiple LocationsEst. completion Apr 30, 2028
Plasmablastic LymphomaHivConsolidation
This is a single-arm feasibility trial in which patients with histologically confirmed plasmablastic lymphoma (PBL) with…
Multiple LocationsEst. completion Dec 1, 2029
Lymphoma, Primary Effusion
Background:
Primary effusion lymphoma (PEL), plasmablastic lymphoma (PBL), and Multicentric Castleman Disease (MCD) are…
Bethesda, United StatesEst. completion Aug 1, 2034